Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 31;109(4):1171–1183. doi: 10.3324/haematol.2023.283352

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2024 Ferrata Storti Foundation

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

PMC Copyright notice

Figure 3. — Patients with MYC^highTP53/p53⁺ form a subgroup with adverse prognosis. (A) Prognostic impact of MYC^highTP53/p53⁺ versus all other states on overall survival. (B) Prognostic impact on overall survival for patients with tumors that were classified only as MYC^high, only TP53/p53⁺, both MYC^highTP53/p53⁺ or wild-type for both markers. (C) Prognostic impact of MYC^highTP53/p53⁺ versus all other patients on progression-free survival. (D) Prognostic impact on progression-free survival for patients with tumors that were classified only as MYC^high, only TP53/p53⁺, both MYC^highTP53/p53⁺ or wild-type for both markers. Kaplan-Meier estimates were calculated and are shown. Log-rank statistics were used to evaluate the statistical significance of differences. WT: wild-type; PFS: progression-free survival.